Tadalafil for Health & Longevity

Created on 10/25/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Tadalafil, a long-acting prescription medication that widens blood vessels, is used for erection problems and urinary symptoms of an enlarged prostate, backed by well-run trials, and treats a rare lung-artery disease. Its longevity case remains uncertain: health-record studies link it to fewer heart attacks and deaths, but healthier habits may partly explain this. Side effects are mostly mild; combining it with heart-pain drugs called nitrates causes dangerous blood-pressure drops. (Full Review)

Protocol

Longevity-oriented daily dose
2.5–5 mg once daily
The label dose for erectile dysfunction and prostate enlargement, offered off-label for longevity by telehealth clinics
Time of day
Any time, with or without food
Evening dosing is often chosen so that peak-level headache coincides with sleep
Baseline biomarkers
2.5 mg daily start at creatinine clearance 30–50 mL/min
In non-responders with testosterone at or below 3 ng/mL, adding testosterone improved response
Time to effect
Erections (daily 5 mg)
Within 2 days
Maximal daily effect may take 12 weeks
As-needed dose
Peak at a median 2 hours
Effect lasts up to 36 hours
Urinary symptoms
Within 1 week
Prostate-related symptoms eased on daily 5 mg

Benefits

Contraindications
  • Users of any organic nitrate or guanylate cyclase stimulator
  • Myocardial infarction within the last 90 days
  • Unstable angina or angina during intercourse
  • Heart failure of NYHA Class 2 or greater within 6 months
  • Uncontrolled arrhythmias
  • Hypotension below 90/50 mm Hg
  • Uncontrolled hypertension
  • Stroke within 6 months
  • Severe hepatic impairment (Child-Pugh Class C)
  • Creatinine clearance below 30 mL/min or hemodialysis, for once-daily use
  • Hereditary degenerative retinal disorders, including retinitis pigmentosa
  • Prior serious hypersensitivity to tadalafil
  • Pulmonary veno-occlusive disease
  • Prior NAION, unless anticipated benefit outweighs risk
Key Interactions
  • Alpha-blockers (doxazosin, tamsulosin)
  • Antihypertensives (amlodipine, enalapril)
  • Oral minoxidil and other direct vessel-widening antihypertensives
  • Alcohol (5 or more units)
  • Potent CYP3A4 inhibitors (ketoconazole, ritonavir)
  • Moderate CYP3A4 inhibitors and grapefruit juice (erythromycin)
  • CYP3A4 inducers (rifampin, carbamazepine)
  • Bosentan
  • Linagliptin
  • Other PDE5 inhibitors (sildenafil, vardenafil)
  • Sexual-enhancement supplements adulterated with PDE5 inhibitors
  • L-arginine
  • Chlorpromazine
  • Theophylline
  • Finasteride
Theoretical (inferred from mechanism)
  • L-citrulline
  • Dietary nitrate concentrates (beetroot juice concentrates)
  • Icariin (horny goat weed extract)
  • St John's wort

Risk & Side Effects

  • High: Headache, dyspepsia, back pain, myalgia and flushing
  • Medium: Symptomatic low blood pressure with nitrates, doxazosin or heavy alcohol; reduced sperm concentration
  • Low: Nonarteritic anterior ischemic optic neuropathy; sudden sensorineural hearing loss; color vision changes; retinal vascular occlusion and serous retinal detachment; melanoma; cardiac events during use; priapism; serious skin reactions; seizures and transient global amnesia
  • Speculative: Arteritis signal from animal toxicology

Monitoring

Marker Target Why
Blood pressure (seated and standing) Resting at or above 90/50 mm Hg Safety check: hypotension stops or changes use
Creatinine clearance or eGFR Creatinine clearance above 50 mL/min for standard dosing Safety check: low values change or rule out daily dose
Liver panel (ALT, bilirubin, albumin) ALT 7–56 U/L Safety check: severe impairment rules out use
IIEF-EF score No established target; track change from own baseline Expected to change with treatment
IPSS No established target; track change from own baseline Expected to change in men with prostate symptoms
HbA1c 4.0–5.6% Expected to change modestly in type 2 diabetes
Semen analysis (if planning conception) Sperm concentration 16 million/mL or more Safety check: falls may prompt stopping

Cadence: Standing blood pressure and symptom scores at 1 and 4 weeks after starting or changing dose; then blood pressure, kidney function and symptom scores every 6–12 months; HbA1c every 6–12 months in people with diabetes; repeat semen analysis after about 3 months of use in men planning conception.

Qualitative Assessment

  • Erection quality, morning erections and sexual confidence
  • Urinary stream, urgency and night-time urination
  • Headache, indigestion, back or muscle pain after doses
  • Dizziness or light-headedness on standing
  • Any change in vision (including blue-tinged or blurred vision) or hearing
  • Exercise tolerance and sense of circulation in hands and feet